Haleos Labs Ltd

Haleos Labs Limited share price remained flat to Rs 1582.85 after the company's net profit saw a strong growth of 441.18% to Rs 1.84 crore, while revenue from operations eased by 2.93% to Rs 72.94 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.82 lakh crore, easing 6.19%. It has marginally improved by 0.41% over last one week and heading higher by 11.45% in last one month while the market capitalization of Haleos Labs Limited has improved by 2.38% and 2.05% in the same period respectively. Profit before tax (PBT) of Haleos Labs Limited stood at Rs 3.44 crore in Q2 FY26, tumbling by 51.00% year-on-year, and expanding by 278.02% quarter-on-quarter. EBITDA came in at Rs 9 crore, tanking 19.14% YoY and rallying 302.79% sequentially. Total expenses marginally dropped 9.03% to Rs 68.07 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 40.14 crore, going up by 11.94% YoY, while employee benefits expense was at Rs 17.55 crore, rising by 8.53% YoY. For the TTM ended FY26, revenue from operations rose 12.67% to Rs 344.72 crore, while net profit jumped 195.89% to Rs 18.73 crore, compared to previous TTM. EBITDA soared by 2635% to Rs 40.18 crore, and PBT witnessed a strong rise of 165.89% to Rs 26.19 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 34.06 crore in FY26, as against Rs 24.31 crore in FY25. Haleos Labs Limited rallied 42.09% in last one year, significantly outperforming the benchmark BSE Sensex which has eased by 3.20% during the same period.

Haleos labs announced that the Board of Directors of the Company at its meeting held on 29 May 2026, inter alia, have recommended the final dividend of Rs 1.5 per equity Share (i.e. 15%) , subject to the approval of the shareholders.

Haleos labs will hold a meeting of the Board of Directors of the Company on 29 May 2026.

Net profit of Haleos Labs rose 21.02% to Rs 6.62 crore in the quarter ended December 2025 as against Rs 5.47 crore during the previous quarter ended December 2024. Sales rose 12.03% to Rs 94.78 crore in the quarter ended December 2025 as against Rs 84.60 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales94.7884.60 12 OPM %14.8215.07 - PBDT12.6910.67 19 PBT8.786.92 27 NP6.625.47 21 Powered by Capital Market - Live

Haleos labs will hold a meeting of the Board of Directors of the Company on 11 February 2026.Powered by Capital Market - Live

Net profit of SMS Lifesciences India rose 30.62% to Rs 6.10 crore in the quarter ended September 2025 as against Rs 4.67 crore during the previous quarter ended September 2024. Sales rose 3.71% to Rs 81.37 crore in the quarter ended September 2025 as against Rs 78.46 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales81.3778.46 4 OPM %16.6810.91 - PBDT12.388.47 46 PBT8.494.70 81 NP6.104.67 31 Powered by Capital Market - Live

SMS LifeSciences India will hold a meeting of the Board of Directors of the Company on 10 November 2025.Powered by Capital Market - Live

SMS LifeSciences India announced that the 19th Annual General Meeting(AGM) of the company will be held on 30 September 2025.Powered by Capital Market - Live

Net profit of SMS Lifesciences India declined 40.57% to Rs 4.16 crore in the quarter ended June 2025 as against Rs 7.00 crore during the previous quarter ended June 2024. Sales declined 10.86% to Rs 82.50 crore in the quarter ended June 2025 as against Rs 92.55 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales82.5092.55 -11 OPM %14.1917.59 - PBDT10.8414.32 -24 PBT7.0210.64 -34 NP4.167.00 -41 Powered by Capital Market - Live

SMS LifeSciences India will hold a meeting of the Board of Directors of the Company on 11 August 2025.Powered by Capital Market - Live